<p>At the beginning of 2025, Sten R. Sörensen announced Cereno Scientific’s positive Phase 2a results in PAH for lead asset CS1. He’s now moving forward with a global Phase 2b trial starting in Q2 2026. The company also progresses its second HDACi asset, CS014, toward Phase 2. Cereno&#39;s developing pioneering treatments with disease-modification potential for rare cardiovascular and pulmonary diseases.---Learn more about Cereno: <a href="https://bit.ly/cereno-e52" target="_blank" rel="noopener noreferer">https://bit.ly/cereno-e52</a>---</p><p>⭐️ ABOUT THE SPEAKER</p><p>Sten joined Cereno as CEO in 2015, with decades of experience in pharma, ranging from Monsanto Pharma to AstraZeneca.</p><p>🔗 LINKS MENTIONED</p><ul><li>Cereno’s website - <a href="https://cerenoscientific.com/" target="_blank" rel="noopener noreferer">https://cerenoscientific.com/</a></li><li>Cereno Scientific | BioStock Life Science Summit 2024 - [<a href="https://www.youtu.be/A5b3Ud_PSas" target="_blank" rel="noopener noreferer">https://www.youtu.be/A5b3Ud_PSas</a>](<a href="https://www.youtube.com/watch?v=A5b3Ud_PSas" target="_blank" rel="noopener noreferer">https://www.youtube.com/watch?v=A5b3Ud_PSas</a>)</li></ul><ul><li>Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in Pulmonary Arterial Hypertension **-** <a href="https://cerenoscientific.com/press-single/?releaseIdentifier=2D7F159764FDB891" target="_blank" rel="noopener noreferer">https://cerenoscientific.com/press-single/?releaseIdentifier=2D7F159764FDB891</a></li><li>Cereno&#39;s HDAC inhibitor reduces risks from pulmonary arterial hypertension in phase 2 trial **-** <a href="https://www.fiercebiotech.com/biotech/cerenos-hdac-inhibitor-reduces-risks-pulmonary-arterial-hypertension-phase-2-trial" target="_blank" rel="noopener noreferer">https://www.fiercebiotech.com/biotech/cerenos-hdac-inhibitor-reduces-risks-pulmonary-arterial-hypertension-phase-2-trial</a></li><li>Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH) - <a href="https://cerenoscientific.com/press-single/?releaseIdentifier=008944355F62DA91" target="_blank" rel="noopener noreferer">https://cerenoscientific.com/press-single/?releaseIdentifier=008944355F62DA91</a></li><li>Competing drug Winrevair / sotatercept by US Merck - <a href="https://www.drugs.com/winrevair.html" target="_blank" rel="noopener noreferer">https://www.drugs.com/winrevair.html</a></li><p><br></p></ul><p>📜 TRANSCRIPT</p><p>Read the full transcript here: <a href="https://flot.bio/episode/sten-sorensen-cereno-drug-repurposing/" target="_blank" rel="noopener noreferer">https://flot.bio/episode/sten-sorensen-cereno-drug-repurposing/</a></p><p>💸 DONATE</p><p>We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: <a href="https://www.paypal.me/PhilipHemme" target="_blank" rel="noopener noreferer">https://www.paypal.me/PhilipHemme</a></p><p>⭐️ SPONSORSHIP</p><p>Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!</p><p>🫶 FOLLOW US</p><ul><li>Newsletter: <a href="http://eepurl.com/h_fnmH" target="_blank" rel="noopener noreferer">http://eepurl.com/h_fnmH</a></li><li>LinkedIn: <a href="https://www.linkedin.com/company/flot-bio/" target="_blank" rel="noopener noreferer">https://www.linkedin.com/company/flot-bio/</a></li><li>X (Twitter): <a href="https://x.com/FlotBio" target="_blank" rel="noopener noreferer">https://x.com/FlotBio</a></li></ul><p><br></p><p>🙏 LIKE/FOLLOW/REVIEW</p><p>Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.</p><p>🎙️ABOUT FLOT.BIO</p><p>Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.</p><p>⏰ TIMESTAMPS</p><ul><li>[00:00:00] Intro</li><li>[00:02:04] Cereno&#39;s Phase2A results</li><li>[00:21:59] Phase2B</li><li>[00:32:41] Cereno&#39;s pipeline</li><li>[00:40:56] The finances of running a Phase2B</li><li>[00:45:07] Investor base of Cereno</li><li>[00:50:42] A strong team is crucial for Cereno</li><li>[00:55:41] The Swedish biotech ecosystem</li><li>[01:02:54] Sten Sörensen&#39;s background</li><li>[01:10:39] Success in drug repurposing</li><li>[01:16:03] Quickfire</li></ul>